Loading
A rice-grain-sized implant releases microdoses of up to 20 drugs into separate spots of a tumour for one to three days, then is removed so pathologists can see which drug worked in that person's own tumour. First-in-human studies have been done in breast, sarcoma and brain tumours.
Implantable microdevices developed at MIT and Brigham and Women's Hospital deliver microdoses of up to 20 agents into spatially separated tumour regions for 24-72 hours before retrieval and analysis, and first-in-human studies have been performed in breast, sarcoma and brain tumours. Applied to immune-modulating agents, the device measures local pharmacodynamics in the real human microenvironment, which no model reproduces.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Cold tumours and the immunosuppressive microenvironment, Glioma & glioblastoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Cold tumours and the immunosuppressive microenvironment, Sarcomas (soft tissue, bone, GIST).
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.
Shares Functional (ex vivo) drug testing, Single-cell & spatial profiling, Lab models that fail to predict what happens in patients.
Shares Functional (ex vivo) drug testing, Single-cell & spatial profiling, Lab models that fail to predict what happens in patients.
Shares Single-cell & spatial profiling, Lab models that fail to predict what happens in patients, Too many combinations to test.
Shares Lab models that fail to predict what happens in patients, Sarcomas (soft tissue, bone, GIST), Glioma & glioblastoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.